October 25, 2014 3:35 AM ET


Company Overview of Eleven Biotherapeutics, Inc.

Company Overview

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal product candidate includes the EBI-005, a novel IL-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and in Phase II clinical trial for the treatment of allergic conjunctivitis. The company’s preclinical product candidates comprise EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of retinal diseases, such ...

215 First Street

Suite 400

Cambridge, MA 02142

United States

Founded in 2008

15 Employees





Key Executives for Eleven Biotherapeutics, Inc.

Chief Executive Officer
Age: 55
Total Annual Compensation: $459.4K
Chief Development Officer
Age: 52
Total Annual Compensation: $198.0K
Chief Scientific Officer
Age: 55
Total Annual Compensation: $344.5K
Compensation as of Fiscal Year 2013.

Eleven Biotherapeutics, Inc. Key Developments

Eleven Biotherapeutics Appoints Wendy L. Dixon to Board of Directors

Eleven Biotherapeutics announced the appointment of Wendy L. Dixon, PhD, former Chief Marketing Officer and President of Global Marketing for Bristol Myers Squibb, to the company's Board of Directors. Dr. Dixon brings 35 years of industry experience to the Eleven Biotherapeutics Board of Directors. Most recently, she was a senior advisor to The Monitor Group, now Monitor Deloitte, from 2010 to 2012.

Eleven Biotherapeutics, Inc. Announces Results from Phase II Allergic Conjunctivitis Study

Eleven Biotherapeutics, Inc. has announced results from a Phase II study of its lead drug candidate, EBI-005, in patients with moderate to severe allergic conjunctivitis. The company ran this Phase II study using two distinct repetitive allergen challenge models: a modified Conjunctival Allergen Provocation Test (CAPT) model; and a modified Environmental Exposure Chamber (EEC) model. In the CAPT model, patients treated with EBI-005 showed statistically significant improvements in mean change from baseline in patient reported ocular itching compared to vehicle-control, one of the secondary endpoints pre-specified in the statistical analysis plan, at the second to last (p = 0.033) and final (p = 0.045) assessment time points. This Phase II study did not meet the primary endpoint of reduction in mean ocular itching in patients treated with EBI-005 compared to vehicle-control in the EEC model.

Eleven Biotherapeutics, Inc. - Special Call

To discuss the top-line Phase 2 clinical study results of EBI-005 in allergic conjunctivitis

Similar Private Companies By Industry

Company Name Region
Hairbiotech Inc United States
Centrillion Biosciences Inc. United States
Ixion Biotechnology, Inc. United States
Civitas Therapeutics, Inc. United States
Annovis, Inc. United States

Recent Private Companies Transactions

Private Placement
December 4, 2013

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eleven Biotherapeutics, Inc., please visit www.elevenbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.